Education
About Us
Working with TipRanks
Follow Us
BridgeBio Pharma Inc (BBIO)
NASDAQ:BBIO
BBIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$21.72 - $49.77
Previous CloseN/A
Volume379.31K
Average Volume (3M)2.79M
Market Cap
$9.38B
Enterprise Value$10.16B
Total Cash (Recent Filing)$756.89M
Total Debt (Recent Filing)$8.81M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Oct 30, 2025EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding191,168,500
10 Day Avg. Volume3,803,762
30 Day Avg. Volume2,789,617
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)-3.50
Price to Sales (P/S)23.01
P/FCF Ratio-9.79
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue51.62
Enterprise Value/Gross Profit52.71
Enterprise Value/Ebitda-15.99
Forecast
1Y Price Target
$60.12Price Target Upside22.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBridgeBio is well-positioned financially with cash on hand, a growing top-line, and flattening or declining expenses.
Market LeadershipAttruby is expected to become the market share leader in the ATTR-CM market, indicating strong potential for future growth.
Bears Say
Investor ConcernsDespite strong quarterly growth, BBIO shares dropped over 10% after-hours, reflecting investor concern over the crowded bullish positioning.
Market CompetitionStrong new patient demand for Attruby persists despite competition, yet investor concerns over market saturation remain prevalent.
BridgeBio Pharma News
BBIO FAQ
What was BridgeBio Pharma Inc’s price range in the past 12 months?
BridgeBio Pharma Inc lowest stock price was $21.72 and its highest was $49.77 in the past 12 months.
What is BridgeBio Pharma Inc’s market cap?
BridgeBio Pharma Inc’s market cap is $9.38B.
When is BridgeBio Pharma Inc’s upcoming earnings report date?
BridgeBio Pharma Inc’s upcoming earnings report date is Oct 30, 2025 which is in 77 days.
How were BridgeBio Pharma Inc’s earnings last quarter?
BridgeBio Pharma Inc released its earnings results on Aug 05, 2025. The company reported -$0.95 earnings per share for the quarter, missing the consensus estimate of -$0.793 by -$0.157.
Is BridgeBio Pharma Inc overvalued?
According to Wall Street analysts BridgeBio Pharma Inc’s price is currently Undervalued.
Does BridgeBio Pharma Inc pay dividends?
BridgeBio Pharma Inc does not currently pay dividends.
What is BridgeBio Pharma Inc’s EPS estimate?
BridgeBio Pharma Inc’s EPS estimate is -0.84.
How many shares outstanding does BridgeBio Pharma Inc have?
BridgeBio Pharma Inc has 191,168,500 shares outstanding.
What happened to BridgeBio Pharma Inc’s price movement after its last earnings report?
BridgeBio Pharma Inc reported an EPS of -$0.95 in its last earnings report, missing expectations of -$0.793. Following the earnings report the stock price went down -8.941%.
Which hedge fund is a major shareholder of BridgeBio Pharma Inc?
Currently, no hedge funds are holding shares in BBIO
BridgeBio Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$60.12 (22.47% Upside)
$60.12 (22.47% Upside)
Blogger Sentiment
Bullish
BBIO Sentiment 85%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 5.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $359.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.0%
Last 30 Days ▲ 8.3%
Last 30 Days ▲ 8.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
104.03%
12-Months-Change
Fundamentals
Return on Equity
35.68%
Trailing 12-Months
Asset Growth
35.98%
Trailing 12-Months
Company Description
BridgeBio Pharma Inc
BridgeBio Pharma (BBIO) is a biotechnology company focused on developing innovative therapeutics for genetic diseases and cancers. The company operates primarily in the pharmaceutical sector, leveraging advanced genetic insights to identify and develop targeted therapies. BridgeBio specializes in creating treatments that address the underlying genetic causes of diseases, with a robust pipeline of product candidates across various stages of clinical development.
BBIO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presents a predominantly positive outlook with a strong performance of Attruby, significant revenue growth, and promising pipeline advancements. However, increased operating expenses and competitive pressures are noted challenges.View all BBIO earnings summariesBBIO Stock 12 Month Forecast
Average Price Target
$60.12
▲(22.47% Upside)
Technical Analysis
Ownership Overview
21.71% Insiders
17.95% Mutual Funds
0.32% Other Institutional Investors
45.72% Public Companies and Individual Investors